Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMOFCRY)

• Drug Name: SEROTONIN Drug Info
• Synonyms: serotonin; 5-HYDROXYTRYPTAMINE; 3-(2-Aminoethyl)-1H-indol-5-ol; 50-67-9; Enteramine; 5-HT; Serotonine; Thrombotonin; Thrombocytin; Antemovis; Ds substance; Hippophain; Antemoqua; Substance DS; Substanz DS; 1H-Indol-5-ol, 3-(2-aminoethyl)-; 5-Hta; Tryptamine, 5-hydroxy-; 3-(2-Aminoethyl)indol-5-ol; Enteramin; UNII-333DO1RDJY; Indol-5-ol, 3-(2-aminoethyl)-; 5-Hydroxy-3-(beta-aminoethyl)indole; 3-(beta-Aminoethyl)-5-hydroxyindole; EINECS 200-058-9; 3-(2-Amino-ethyl)-1H-indol-5-ol; BRN 0143524; 333DO1RDJY; CHEBI:28790

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 5202
  ChEBI ID: CHEBI:28790
  CAS Number: CAS 50-67-9
  TTD Drug ID: DMOFCRY
  VARIDT Drug ID: DR00189
  INTEDE Drug ID: DR1961

Molecule-Related Drug Atlas

Drug(s) Targeting 5-HT 1B receptor (HTR1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[26]
Eletriptan	DMW649X	Migraine	8A80	Approved	[27]
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[27]
Frovatriptan	DM7RE8P	Migraine	8A80	Approved	[27]
Fluphenazine	DMIT8LX	Psychotic disorder	6A20-6A25	Approved	[27]
Naratriptan	DMO50U2	Headache	8A80-8A84	Approved	[28]
Prolixin decanoate	DMMJ1IS	Schizophrenia	6A20	Approved	[27]
Eltoprazine	DMW6C81	Attention deficit hyperactivity disorder	6A05.Z	Phase 3	[29]
NXN-188	DMMBAIH	Migraine	8A80	Phase 2	[30]
[N-methyl-3H(3)]AZ-10419369	DMSCV02	Mood disorder	6A60-6E23	Phase 1	[31]

Drug(s) Targeting 5-HT 1D receptor (HTR1D)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[32]
Eletriptan	DMW649X	Migraine	8A80	Approved	[27]
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[27]
Frovatriptan	DM7RE8P	Migraine	8A80	Approved	[27]
Sumatriptan	DMVYXR8	Cluster headache	8A81.0	Approved	[33]
Rizatriptan	DMDJMA3	Migraine	8A80	Approved	[34]
Almogran	DM7I64Z	Migraine	8A80	Approved	[35]
Neu-P11	DMIQDFW	Alzheimer disease	8A20	Phase 2	[36]
FKB01MD	DM2O7NM	N. A.	N. A.	Phase 2	[37]
NXN-188	DMMBAIH	Migraine	8A80	Phase 2	[30]

Drug(s) Targeting 5-HT 5A receptor (HTR5A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[38]
(+/-)-nantenine	DM0L3GE	Discovery agent	N.A.	Investigative	[39]
5-CT	DM260KD	Discovery agent	N.A.	Investigative	[40]
TFMPP	DMAC8TP	Discovery agent	N.A.	Investigative	[41]
5,6-dichloro-3,4-dihydroquinazolin-2-amine	DMN1S35	Discovery agent	N.A.	Investigative	[42]
MPDT	DMYX31S	Discovery agent	N.A.	Investigative	[43]
5-chloro-3,4-dihydroquinazolin-2-amine	DMKEFJ0	Discovery agent	N.A.	Investigative	[42]
EDMT	DMS3AXK	Discovery agent	N.A.	Investigative	[43]
5-chloro-4-methyl-3,4-dihydroquinazolin-2-amine	DM7FZU2	Discovery agent	N.A.	Investigative	[42]
[3H]5-CT	DMEAHFZ	Discovery agent	N.A.	Investigative	[44]

Drug(s) Targeting 5-HT 6 receptor (HTR6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LU AE58054	DMWGRQD	Schizophrenia	6A20	Phase 3	[45]
SB-742457	DM6L4ZT	Alzheimer disease	8A20	Phase 3	[46]
AVN 211	DMVB4OS	Schizophrenia	6A20	Phase 2/3	[47]
SYN120	DMDF7XB	Parkinson disease	8A00.0	Phase 2	[48]
AVN 101	DMJFLBC	Alzheimer disease	8A20	Phase 2	[47]
SYN-120	DMPW0UL	Alzheimer disease	8A20	Phase 2	[49]
PF-05212377	DMPVQYR	Alzheimer disease	8A20	Phase 2	[50]
AVN 322	DMK2LGM	Cognitive impairment	6D71	Phase 2	[46]
SAM-531	DMHVJZ6	Alzheimer disease	8A20	Phase 2	[51]
SUVN-502	DMQD753	Alzheimer disease	8A20	Phase 2	[52]

Drug(s) Targeting 5-HT 2B receptor (HTR2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[53]
Triflupromazine	DMKFQJP	Nausea	MD90	Approved	[54]
Minaprine	DM0EP7M	Depression	6A70-6A7Z	Approved	[55]
SPN-812	DMTV7XH	Attention deficit hyperactivity disorder	6A05.Z	Phase 4	[56]
Vabicaserin	DM9GZW6	Psychotic disorder	6A20-6A25	Phase 2	[57]
PRX-08066	DMR7H2V	Pulmonary arterial hypertension	BB01.0	Phase 2	[58]
Pyrimidine derivative 29	DMVOYJ8	N. A.	N. A.	Patented	[59]
Pyrimidine derivative 26	DM90WKN	N. A.	N. A.	Patented	[59]
Pyrimidine derivative 23	DM5MLQU	N. A.	N. A.	Patented	[59]
Pyrimidine derivative 25	DM51MFS	N. A.	N. A.	Patented	[59]

Drug(s) Targeting 5-HT 2A receptor (HTR2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[53]
ZOTEPINE	DMF3VXA	Anxiety disorder	6B00-6B0Z	Approved	[60]
Iloperidone	DM6AUFY	Schizophrenia	6A20	Approved	[61]
Flibanserin	DM70DTN	Depression	6A70-6A7Z	Approved	[62]
Lurasidone hydrochloride	DMCVPXO	Schizophrenia	6A20	Approved	[63]
Aniracetam	DMOIFW0	Cerebrovascular ischaemia	8B1Z	Approved	[64]
lumateperone tosylate	DMQ8HOJ	Schizophrenia	6A20	Approved	[65]
Sarpogrelate	DMGLP6S	Diabetic complication	5A2Y	Approved	[66]
Pimavanserin	DMR7IVC	Parkinson disease	8A00.0	Approved	[67]
Zicronapine	DMP8ESD	Schizophrenia	6A20	Phase 3	[68]

Drug(s) Targeting Adenosine A3 receptor (ADORA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IB-MECA	DM9G5XD	Psoriasis vulgaris	EA90	Phase 3	[69]
Tonapofylline	DMBH316	Acute and chronic heart failure	BD1Z	Phase 2	[70]
NITD609	DMQHBSX	Malaria	1F40-1F45	Phase 2	[71]
CF102	DMP56WJ	Hepatocellular carcinoma	2C12.02	Phase 2	[72]
SCH-442416	DMQ2K1V	N. A.	N. A.	Phase 1	[73]
AST-004	DM5WMG7	Stroke	8B20	Phase 1	[74]
BEMESETRON	DMSPJX9	N. A.	N. A.	Discontinued in Phase 3	[10]
BAY 60-6583	DMTEJV1	Myocardial ischemia	BA6Z	Preclinical	[75]
CF602	DM0ULO2	Inflammation	1A00-CA43.1	Preclinical	[72]
CF502	DMQSJ20	Inflammation	1A00-CA43.1	Preclinical	[72]

Drug(s) Targeting 5-HT 3B receptor (HTR3B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BEMESETRON	DMSPJX9	N. A.	N. A.	Discontinued in Phase 3	[76]
2-methyl-5-HT	DM1S5CB	N. A.	N. A.	Investigative	[77]
QUIPAZINE	DMPY6IG	Discovery agent	N.A.	Investigative	[7]
MESULERGINE	DMKGWAH	Discovery agent	N.A.	Investigative	[78]
bilobalide	DM09Z35	Discovery agent	N.A.	Investigative	[79]
2-(4-Methyl-piperazin-1-yl)-quinoline	DMB8OY6	Discovery agent	N.A.	Investigative	[7]
BRL-24682	DMSB4EW	Discovery agent	N.A.	Investigative	[80]
6-(4-Methyl-piperazin-1-yl)-phenanthridine	DM1HAWR	Discovery agent	N.A.	Investigative	[7]
trichloroethanol	DMNALMF	Discovery agent	N.A.	Investigative	[81]
1-phenylbiguanide	DMA4XGL	Discovery agent	N.A.	Investigative	[82]

Drug(s) Targeting 5-HT 4 receptor (HTR4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisapride	DMY7PED	Gastroesophageal reflux disease	DA22.Z	Approved	[83]
Tegaserod	DM3XYD1	Irritable bowel syndrome	DD91.0	Approved	[84]
R0-93877	DMM4U9G	Constipation	DD91.1	Approved	[33]
HTF 919	DM78G6F	Constipation	DD91.1	Approved	[85]
Mosapride	DM2VOQ3	N. A.	N. A.	Phase 4	[86]
Renzapride	DM7HQNX	Irritable bowel syndrome	DD91.0	Phase 3	[87]
Lintopride	DMSHGWN	Nausea	MD90	Phase 2	[88]
TD-8954	DM3C9NV	Gastrointestinal disease	DE2Z	Phase 2	[89]
SB-207266A	DM27KFY	Irritable bowel syndrome	DD91.0	Phase 2	[33]
YKP-GI	DM740LV	Constipation	DD91.1	Phase 2	[90]

Drug(s) Targeting 5-HT 3A receptor (HTR3A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dolasetron	DMMG26Z	Nausea	MD90	Approved	[91]
Alosetron	DML2A03	Diarrhea-predominant irritable bowel syndrome	DD91.01	Approved	[92]
Tropisetron	DMNSJ7V	Fibromyalgia	MG30.01	Approved	[93]
Palonosetron	DMBHMOX	Nausea	MD90	Approved	[94]
Levetiracetam	DMTGDN8	Epilepsy	8A60-8A68	Approved	[93]
Procaine	DM4LSNE	Anaesthesia	9A78.6	Approved	[95]
Cilansetron	DMP0NGX	Irritable bowel syndrome	DD91.0	Phase 3	[96]
BEMESETRON	DMSPJX9	N. A.	N. A.	Discontinued in Phase 3	[76]
Norcisapride	DMJSKUI	Gastroesophageal reflux disease	DA22.Z	Discontinued in Phase 2	[97]
YM-114	DML2IXO	Nausea	MD90	Discontinued in Phase 2	[98]

Drug(s) Targeting 5-HT 1A receptor (HTR1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Trazodone	DMK1GBJ	Depression	6A70-6A7Z	Approved	[27]
Buspirone	DMBS632	Anxiety disorder	6B00-6B0Z	Approved	[99]
OPC-34712	DMHG57U	Major depressive disorder	6A70.3	Approved	[100]
Vilazodone	DM4LECQ	Major depressive disorder	6A70.3	Approved	[101]
Flibanserin	DM70DTN	Depression	6A70-6A7Z	Approved	[62]
Gepirone	DMGX5Q0	Major depressive disorder	6A70.3	Approved	[102]
TERTATOLOL	DM2L3D5	Hypertension	BA00-BA04	Approved	[103]
Urapidil	DMD59GI	Hypertension	BA00-BA04	Approved	[104]
Treximet	DMU54QB	Migraine	8A80	Approved	[105]
CM-2395	DMASPWR	Schizophrenia	6A20	Phase 3	[106]

Drug(s) Targeting 5-HT 7 receptor (HTR7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RP5063	DMKUE8O	Schizophrenia	6A20	Phase 2	[37]
JNJ-18038683	DMV1T59	Major depressive disorder	6A70.3	Phase 2	[107]
AVN-101	DMOGFNI	Cognitive impairment	6D71	Phase 2	[108]
ATI-9242	DM6GKMU	Schizophrenia	6A20	Phase 1	[109]
PMID30124346-Compound-34TABLE4	DM2G3VE	Attention deficit hyperactivity disorder	6A05.Z	Patented	[110]
PMID30124346-Compound-13TABLE4	DMHTJVA	Attention deficit hyperactivity disorder	6A05.Z	Patented	[110]
Carbamide derivative 2	DMW5GI3	N. A.	N. A.	Patented	[111]
4-oxadiazole derivative 1	DMWFHKR	N. A.	N. A.	Patented	[111]
SB-269970	DM8WTGA	Sleep-wake disorder	7A00-7B2Z	Terminated	[112]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	DMM9X0G	Discovery agent	N.A.	Investigative	[113]

Drug(s) Targeting 5-HT 2C receptor (HTR2C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[53]
Lorcaserin	DMG6OYJ	Obesity	5B81	Approved	[114]
Tramadol	DMRQD04	Osteoarthritis	FA00-FA05	Approved	[115]
Mirtazapine	DML53ZJ	Depression	6A70-6A7Z	Approved	[116]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[117]
Methysergide	DM1EF73	Migraine	8A80	Approved	[118]
Eltoprazine	DMW6C81	Attention deficit hyperactivity disorder	6A05.Z	Phase 3	[29]
M100907	DM7ZFBA	Sleep-wake disorder	7A00-7B2Z	Phase 3	[119]
SR46349B	DM1ODMR	Primary insomnia	7A00	Phase 3	[120]
Vabicaserin	DM9GZW6	Psychotic disorder	6A20-6A25	Phase 2	[57]

Drug(s) Transported By Organic cation transporter 2 (SLC22A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[121]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[122]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[123]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[124]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[14]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[125]
Ergotidine	DM78IME	Osteoarthritis	FA00-FA05	Approved	[126]
Metformin	DM89QE1	Colorectal carcinoma		Approved	[127]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[125]
Ranitidine	DM0GUSX	Gastric ulcer	DA60	Approved	[128]

Drug(s) Transported By Vesicular amine transporter 2 (SLC18A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[13]
Ergotidine	DM78IME	Osteoarthritis	FA00-FA05	Approved	[129]
Norepinephrine	DMOUC09	Alopecia	ED70	Approved	[13]
Methamphetamine	DMPM4SK	Anxiety		Approved	[130]

Drug(s) Transported By Vesicular amine transporter 1 (SLC18A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[13]
Ergotidine	DM78IME	Osteoarthritis	FA00-FA05	Approved	[131]
Norepinephrine	DMOUC09	Alopecia	ED70	Approved	[13]

Drug(s) Transported By Equilibrative nucleoside transporter 4 (SLC29A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ergotidine	DM78IME	Osteoarthritis	FA00-FA05	Approved	[132]
Metformin	DM89QE1	Colorectal carcinoma		Approved	[133]
Ergotidine	DM78IME	Osteoarthritis	FA00-FA05	Approved	[158]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[159]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[160]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[161]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[149]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[162]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[163]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[164]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[165]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[158]

Drug(s) Transported By Sodium-dependent serotonin transporter (SLC6A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Oxypertine	DMYKG8R	N. A.	N. A.	Preclinical	[134]
Paroxetine	DM5PVQE	Anxiety disorder	6B00-6B0Z	Approved	[150]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[151]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[152]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[153]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[154]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[155]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[141]
Aripiprazole	DM3NUMH	Bipolar I disorder		Approved	[156]
Gabapentin	DM6T924	Complex partial seizure	8A68.0	Approved	[154]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[157]

Drug(s) Metabolized By Monoamine oxidase type A (MAO-A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[135]
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[136]
Naratriptan	DMO50U2	Headache	8A80-8A84	Approved	[137]
Safinamide mesylate	DM0J2ZT	Parkinson disease	8A00.0	Approved	[138]
Almotriptan malate	DMFG5ST	N. A.	N. A.	Approved	[139]
PHENETHYLAMINE	DMX0G4F	Discovery agent	N.A.	Investigative	[15]
Benzylamine	DMRM6ES	N. A.	N. A.	Investigative	[15]

Drug(s) Affected By Amine oxidase A (MAOA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[140]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[141]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[142]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[143]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[144]
Selegiline	DM6034S	Major depressive disorder	6A70.3	Approved	[145]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[146]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[147]
Clorgyline	DMCEUJD	Parkinson disease	8A00.0	Approved	[148]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[149]

Drug(s) Affected By Chromaffin granule amine transporter (SLC18A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[159]
Permethrin	DMZ0Q1G	Pediculus capitis infestation	1G00.0	Approved	[166]
Reserpine	DM6VM38	Hypertension	BA00-BA04	Approved	[167]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[168]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[169]

Drug(s) Affected By Synaptic vesicular amine transporter (SLC18A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Norepinephrine	DMOUC09	Alopecia	ED70	Approved	[170]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[170]
Methamphetamine	DMPM4SK	Anxiety		Approved	[171]
Ergotidine	DM78IME	Osteoarthritis	FA00-FA05	Approved	[172]
Haloperidol	DM96SE0	Delirium		Approved	[172]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[173]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[149]
Dextroamphetamine	DMMIHVP	Attention deficit hyperactivity disorder	6A05.Z	Approved	[172]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[174]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[175]

Drug(s) Affected By 5-hydroxytryptamine receptor 1D (HTR1D)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[176]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[177]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[178]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[179]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[180]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[181]

Drug(s) Affected By 5-hydroxytryptamine receptor 2B (HTR2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gabapentin	DM6T924	Complex partial seizure	8A68.0	Approved	[167]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[182]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[149]
Mifepristone	DMGZQEF	Cushing disease	5A70	Approved	[183]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[184]
Bortezomib	DMNO38U	Leukemia		Approved	[185]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[186]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[187]
Fenfluramine	DM0762O	Dravet syndrome	8A61.11	Phase 3	[188]
GSK2110183	DMZHB37	leukaemia	2A60-2B33	Phase 2	[189]

Drug(s) Affected By 5-hydroxytryptamine receptor 2A (HTR2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gabapentin	DM6T924	Complex partial seizure	8A68.0	Approved	[167]
Fluphenazine	DMIT8LX	Psychotic disorder	6A20-6A25	Approved	[190]
Paliperidone	DM7NPJS	Psychotic disorder	6A20-6A25	Approved	[191]
Haloperidol	DM96SE0	Delirium		Approved	[191]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[149]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[192]
Olanzapine	DMPFN6Y	Bipolar depression		Approved	[193]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[194]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[195]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[196]

Drug(s) Affected By Tumor necrosis factor (TNF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indomethacin	DMSC4A7	Bursitis		Approved	[197]
Amphotericin B	DMTAJQE	Acne vulgaris	ED80	Approved	[198]
Fructose	DM43AN2	Vomiting	MD90	Approved	[167]
Ketoprofen	DMRKXPT	Bursitis		Approved	[167]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[199]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[200]
Baclofen	DM0QV1J	Multiple sclerosis	8A40	Approved	[201]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[202]
Ganciclovir	DM1MBYQ	Cytomegalovirus infection	1D82	Approved	[203]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[204]

Drug(s) Affected By Interleukin-1 beta (IL1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[205]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[206]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[207]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[208]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[209]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[208]
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[210]
Selenium	DM25CGV	N. A.	N. A.	Approved	[211]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[212]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[213]

Drug(s) Affected By Interleukin-6 (IL6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[214]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[215]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[176]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[216]
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[217]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[206]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[204]
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[210]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[218]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[214]

Drug(s) Affected By Interleukin-8 (CXCL8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[219]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[220]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[221]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[216]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[222]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[206]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[208]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[209]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[223]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[208]

Drug(s) Affected By Cystic fibrosis transmembrane conductance regulator (CFTR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ivacaftor	DMZC1HS	Cystic fibrosis	CA25	Approved	[224]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[152]
Rhucin	DM3ADGP	Erectile dysfunction	HA01.1	Approved	[225]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[226]
Miglustat	DM5J64S	Niemann-Pick disease type C		Approved	[227]
Glibenclamide	DM8JXPZ	Diabetic complication	5A2Y	Approved	[228]
Milrinone	DM8TUPF	Congestive heart failure	BD10	Approved	[225]
Oxidized glutathione	DM9EQC0	Breast cancer	2C60-2C65	Approved	[229]
Glutathione	DMAHMT9	Human immunodeficiency virus infection	1C62	Approved	[229]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[230]

Drug(s) Affected By Acetyl-CoA acetyltransferase, mitochondrial (ACAT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[141]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[231]
Haloperidol	DM96SE0	Delirium		Approved	[232]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[147]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[149]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[233]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[234]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[235]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[192]
Pioglitazone	DMKJ485	Amyotrophic lateral sclerosis	8B60.0	Approved	[235]

Drug(s) Affected By Mitogen-activated protein kinase 3 (MAPK3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[236]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[237]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[238]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[200]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[239]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[240]
Secobarbital	DM14RF5	Epilepsy	8A60-8A68	Approved	[241]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[242]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[243]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[244]

Drug(s) Affected By Mitogen-activated protein kinase 1 (MAPK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[245]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[237]
Carvedilol	DMHTEAO	Chronic heart failure	BD1Z	Approved	[246]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[247]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[248]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[236]
Urokinase	DM0GOUD	Myocardial infarction	BA41-BA43	Approved	[167]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[205]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[200]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[239]

Drug(s) Affected By Interleukin-12 subunit beta (IL12B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[249]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[250]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[251]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[252]
Ergotidine	DM78IME	Osteoarthritis	FA00-FA05	Approved	[253]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[254]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[255]
Azacitidine	DMTA5OE	Acute myelogenous leukaemia	2A41	Approved	[256]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[257]
Bryostatin-1	DM1JOXY	Alzheimer disease	8A20	Phase 2	[258]

Drug(s) Affected By Peroxisome proliferator-activated receptor gamma (PPARG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[259]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[260]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[261]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[262]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[263]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[264]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[265]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[266]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[267]
Stavudine	DM6DEK9	Human immunodeficiency virus infection	1C62	Approved	[268]

Drug(s) Affected By Serine/threonine-protein kinase mTOR (MTOR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[269]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[270]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[271]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[272]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[273]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[274]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[154]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[275]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[276]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[277]

Drug(s) Affected By Glycogen synthase kinase-3 beta (GSK3B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[278]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[279]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[280]
Selenium	DM25CGV	N. A.	N. A.	Approved	[281]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[282]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[283]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[284]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[285]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[159]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[286]

Drug(s) Affected By Transcription factor p65 (RELA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[205]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[287]
Selenium	DM25CGV	N. A.	N. A.	Approved	[281]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[288]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[289]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[290]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[141]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[291]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[292]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[293]

Drug(s) Affected By Aquaporin-3 (AQP3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[281]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[294]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[141]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[143]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[295]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[296]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[173]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[147]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[149]
Ampicillin	DMHWE7P	Acute epiglottitis		Approved	[141]

Drug(s) Affected By Sortilin-related receptor (SORL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[152]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[263]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[297]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[173]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[297]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[297]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[147]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[298]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[297]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[297]

Drug(s) Affected By Sulfotransferase 1A1 (SULT1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[299]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[300]
Minoxidil	DMA2Z4F	Alopecia	ED70	Approved	[301]
Benzyl alcohol	DMBVYDI	Head and body lice	1G00.0	Approved	[302]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[301]
Meclofenamic acid	DM05FXR	Ankylosing spondylitis	FA92.0	Approved	[303]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[304]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[305]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[141]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[159]

Drug(s) Affected By Poly polymerase 1 (PARP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[176]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[306]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[307]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[308]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[309]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[310]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[309]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[311]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[312]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[313]

Drug(s) Affected By Sodium-dependent dopamine transporter (SLC6A3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[314]
Amphetamine	DMSZQAK	Attention deficit hyperactivity disorder	6A05.Z	Approved	[315]
Bupropion	DM5PCS7	Depression	6A70-6A7Z	Approved	[316]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[182]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[317]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[317]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[149]
Dextroamphetamine	DMMIHVP	Attention deficit hyperactivity disorder	6A05.Z	Approved	[318]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[319]
Permethrin	DMZ0Q1G	Pediculus capitis infestation	1G00.0	Approved	[320]

Drug(s) Affected By Tryptophan 5-hydroxylase 1 (TPH1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[304]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[194]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[321]

Drug(s) Affected By Sulfotransferase 1A3 (SULT1A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[299]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[322]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[149]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[323]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[324]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[325]
Vitamin C	DMXJ7O8	Adenocarcinoma	2D40	Approved	[326]
Benzyl alcohol	DMBVYDI	Head and body lice	1G00.0	Approved	[302]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[301]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[301]

Drug(s) Affected By Amyloid-beta precursor protein (APP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[327]
Selenium	DM25CGV	N. A.	N. A.	Approved	[281]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[328]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[329]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[142]
Penicillamine	DM40EF6	Cystinuria	5C60.2	Approved	[330]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[331]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[332]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[333]
Aluminium	DM6ECN9	Hyperhidrosis	EE00	Approved	[334]

Drug(s) Affected By Nitric oxide synthase, inducible (NOS2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[335]
Indomethacin	DMSC4A7	Bursitis		Approved	[336]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[337]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[338]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[140]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[339]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[340]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[341]
Penicillamine	DM40EF6	Cystinuria	5C60.2	Approved	[342]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[343]

Drug(s) Affected By Solute carrier family 22 member 3 (SLC22A3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[158]
Ergotidine	DM78IME	Osteoarthritis	FA00-FA05	Approved	[158]
Norepinephrine	DMOUC09	Alopecia	ED70	Approved	[158]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[344]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[141]
Phenoxybenzamine	DM8KSQH	Malignant essential hypertension	BA00	Approved	[345]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[147]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[346]
Enzalutamide	DMGL19D	Prostate cancer	2C82.0	Approved	[347]
Mifepristone	DMGZQEF	Cushing disease	5A70	Approved	[183]

Drug(s) Affected By Amine oxidase B (MAOB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[21]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[140]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[141]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[348]
Selegiline	DM6034S	Major depressive disorder	6A70.3	Approved	[349]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[350]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[147]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[149]
BENZYL BENZOATE	DMDPYI5	Infestations of lice and scabies	1G00.Z	Approved	[351]
Linezolid	DMGFPU2	Bacteremia	1A73	Approved	[352]

Drug(s) Affected By Syntaxin-binding protein 3 (STXBP3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[353]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[233]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[165]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[354]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[355]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[356]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[357]

Drug(s) Affected By Integrin beta-3 (ITGB3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[358]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[359]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[360]
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[361]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[362]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[363]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[364]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[165]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[299]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[365]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 1A receptor (HTR1A)	TTSQIFT	5HT1A_HUMAN	Inhibitor	[2]
5-HT 1B receptor (HTR1B)	TTK8CXU	5HT1B_HUMAN	Inhibitor	[3]
5-HT 1D receptor (HTR1D)	TT6MSOK	5HT1D_HUMAN	Inhibitor	[4]
5-HT 2A receptor (HTR2A)	TTJQOD7	5HT2A_HUMAN	Inhibitor	[2]
5-HT 2B receptor (HTR2B)	TT0K1SC	5HT2B_HUMAN	Inhibitor	[5]
5-HT 2C receptor (HTR2C)	TTWJBZ5	5HT2C_HUMAN	Inhibitor	[6]
5-HT 3A receptor (HTR3A)	TTPC4TU	5HT3A_HUMAN	Inhibitor	[7]
5-HT 3B receptor (HTR3B)	TTR6K75	5HT3B_HUMAN	Inhibitor	[7]
5-HT 4 receptor (HTR4)	TT07C3Y	5HT4R_HUMAN	Inhibitor	[6]
5-HT 5A receptor (HTR5A)	TTRUFDT	5HT5A_HUMAN	Inhibitor	[8]
5-HT 6 receptor (HTR6)	TTJS8PY	5HT6R_HUMAN	Inhibitor	[9]
5-HT 7 receptor (HTR7)	TTO9X1H	5HT7R_HUMAN	Inhibitor	[8]
Adenosine A3 receptor (ADORA3)	TTJFY5U	AA3R_HUMAN	Inhibitor	[10]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Sodium-dependent serotonin transporter (SLC6A4)	DTAV4SY	SC6A4_HUMAN	Substrate	[11]
Equilibrative nucleoside transporter 4 (SLC29A4)	DT3EAQP	S29A4_HUMAN	Substrate	[12]
Vesicular amine transporter 2 (SLC18A2)	DTT7VPB	VMAT2_HUMAN	Substrate	[13]
Vesicular amine transporter 1 (SLC18A1)	DTM953D	VMAT1_HUMAN	Substrate	[13]
Organic cation transporter 2 (SLC22A2)	DT9IDPW	S22A2_HUMAN	Substrate	[14]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Monoamine oxidase type A (MAO-A) Main DME	DERE4TU	AOFA_HUMAN	Substrate	[15]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
5-hydroxytryptamine receptor 1D (HTR1D)	OTLS74AF	5HT1D_HUMAN	Regulation of Drug Effects	[16]
5-hydroxytryptamine receptor 2A (HTR2A)	OTWXJX0M	5HT2A_HUMAN	Drug Response	[17]
5-hydroxytryptamine receptor 2B (HTR2B)	OTM1AD9J	5HT2B_HUMAN	Protein Interaction/Cellular Processes	[18]
Acetyl-CoA acetyltransferase, mitochondrial (ACAT1)	OTJC60Q7	THIL_HUMAN	Gene/Protein Processing	[19]
Amine oxidase A (MAOA)	OT8NIWMQ	AOFA_HUMAN	Regulation of Drug Effects	[20]
Amine oxidase B (MAOB)	OTTDFM1O	AOFB_HUMAN	Biotransformations	[21]
Amyloid-beta precursor protein (APP)	OTKFD7R4	A4_HUMAN	Drug Response	[22]
Aquaporin-3 (AQP3)	OT2J7JPD	AQP3_HUMAN	Gene/Protein Processing	[23]
Chromaffin granule amine transporter (SLC18A1)	OT01OALS	VMAT1_HUMAN	Regulation of Drug Effects	[24]
Cystic fibrosis transmembrane conductance regulator (CFTR)	OT6B22QH	CFTR_HUMAN	Gene/Protein Processing	[25]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5).
• [2] Novel, potent, and selective quinoxaline-based 5-HT(3) receptor ligands. 1. Further structure-activity relationships and pharmacological characteri... J Med Chem. 2009 Nov 12;52(21):6946-50.
• [3] cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
• [4] Designing selective, high affinity ligands of 5-HT1D receptor by covalent dimerization of 5-HT1F ligands derived from 4-fluoro-N-[3-(1-methyl-4-pip... J Med Chem. 2008 Jun 26;51(12):3609-16.
• [5] Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists. Bioorg Med Chem Lett. 2006 Feb;16(3):677-80.
• [6] Brominated cyclodipeptides from the marine sponge Geodia barretti as selective 5-HT ligands. J Nat Prod. 2006 Oct;69(10):1421-4.
• [7] Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy ... J Med Chem. 1999 May 6;42(9):1556-75.
• [8] Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69.
• [9] 5-Cyclic amine-3-arylsulfonylindazoles as novel 5-HT6 receptor antagonists. J Med Chem. 2010 Mar 25;53(6):2521-7.
• [10] 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96.
• [11] Serotonin transporter gene, depressive symptoms, and interleukin-6. Circ Cardiovasc Genet. 2009 Dec;2(6):614-20.
• [12] Autism spectrum disorder associated with low serotonin in CSF and mutations in the SLC29A4 plasma membrane monoamine transporter (PMAT) gene. Mol Autism. 2014 Aug 13;5:43.
• [13] SLC18: Vesicular neurotransmitter transporters for monoamines and acetylcholine. Mol Aspects Med. 2013 Apr-Jun;34(2-3):360-72.
• [14] Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.
• [15] Do monomeric vs dimeric forms of MAO-A make a difference? A direct comparison of the catalytic properties of rat and human MAO-A's. J Neural Transm (Vienna). 2007;114(6):721-4.
• [16] Evidence for epistasis between SLC6A4 and ITGB3 in autism etiology and in the determination of platelet serotonin levels. Hum Genet. 2007 Apr;121(2):243-56. doi: 10.1007/s00439-006-0301-3. Epub 2007 Jan 3.
• [17] Pharmacologic analysis of non-synonymous coding h5-HT2A SNPs reveals alterations in atypical antipsychotic and agonist efficacies. Pharmacogenomics J. 2006 Jan-Feb;6(1):42-51. doi: 10.1038/sj.tpj.6500342.
• [18] A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT2A receptor. J Med Chem. 1998 Dec 17;41(26):5148-9. doi: 10.1021/jm9803525.
• [19] Serotonin acts as an up-regulator of acyl-coenzyme A:cholesterol acyltransferase-1 in human monocyte-macrophages. Atherosclerosis. 2006 Jun;186(2):275-81. doi: 10.1016/j.atherosclerosis.2005.08.007. Epub 2005 Sep 12.
• [20] Hyperserotonemia in autism: the potential role of 5HT-related gene variants. Coll Antropol. 2008 Jan;32 Suppl 1:75-80.
• [21] Inhibition potential of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites on the in vitro monoamine oxidase (MAO)-catalyzed deamination of the neurotransmitters serotonin and dopamine. Toxicol Lett. 2016 Jan 22;243:48-55.
• [22] Rose Essential Oil Delayed Alzheimer's Disease-Like Symptoms by SKN-1 Pathway in C. elegans. J Agric Food Chem. 2017 Oct 11;65(40):8855-8865. doi: 10.1021/acs.jafc.7b03224. Epub 2017 Sep 27.
• [23] Morphine-Induced Constipation Develops With Increased Aquaporin-3 Expression in the Colon via Increased Serotonin Secretion. Toxicol Sci. 2015 Jun;145(2):337-47. doi: 10.1093/toxsci/kfv055. Epub 2015 Mar 12.
• [24] Functional identification and molecular cloning of a human brain vesicle monoamine transporter. J Neurochem. 1993 Dec;61(6):2314-7. doi: 10.1111/j.1471-4159.1993.tb07476.x.
• [25] Involvement of G protein betagamma-subunits in diverse signaling induced by G(i/o)-coupled receptors: study using the Xenopus oocyte expression system. Am J Physiol Cell Physiol. 2004 Oct;287(4):C885-94. doi: 10.1152/ajpcell.00125.2004. Epub 2004 May 19.
• [26] Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors. J Neurochem. 1996 Nov;67(5):2096-103.
• [27] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [28] Triptans in pregnancy. Ther Drug Monit. 2008 Feb;30(1):5-9.
• [29] Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
• [30] Company report (NeurAxon)
• [31] 5-HT1B and other related serotonergic proteins are altered in APPswe mutation. Neurosci Lett. 2015 May 6;594:137-43.
• [32] Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143-8.
• [33] Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
• [34] An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210.
• [35] Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study. Clin Ther. 2001 Nov;23(11):1867-75.
• [36] Clinical pipeline report, company report or official report of Neurim Pharmaceuticals.
• [37] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [38] Cloning and characterisation of the human 5-HT5A serotonin receptor. FEBS Lett. 1994 Dec 5;355(3):242-6.
• [39] Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
• [40] Expression of functional mouse 5-HT5A serotonin receptor in the methylotrophic yeast Pichia pastoris: pharmacological characterization and localization. FEBS Lett. 1995 Dec 27;377(3):451-6.
• [41] Mouse 5-hydroxytryptamine5A and 5-hydroxytryptamine5B receptors define a new family of serotonin receptors: cloning, functional expression, and chromosomal localization. Mol Pharmacol. 1993 Mar;43(3):313-9.
• [42] Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61.
• [43] 2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem. 2000 Mar 9;43(5):1011-8.
• [44] Human 5-HT(5) receptors: the 5-HT(5A) receptor is functional but the 5-HT(5B) receptor was lost during mammalian evolution. Eur J Pharmacol. 2001 Apr 27;418(3):157-67.
• [45] Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol. 2010 Sep;13(8):1021-33.
• [46] 5-HT6 receptors and Alzheimer's disease. Alzheimers Res Ther. 2013; 5(2): 15.
• [47] Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. Curr Opin Investig Drugs. 2010 January; 11(1): 80-91.
• [48] Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov. 2018 Nov;17(11):804-822.
• [49] The Serotonin-6 Receptor as a Novel Therapeutic Target. Exp Neurobiol. 2011 December; 20(4): 159-168.
• [50] PF-05212377 Alzheimer's Disease (Phase 2). Pfizer.
• [51] Activation of 5-HT6 receptors modulates sleep-wake activity and hippocampal theta oscillation. ACS Chem Neurosci. 2013 Jan 16;4(1):191-9.
• [52] Novel and Potent 5-Piperazinyl Methyl-N1-aryl Sulfonyl Indole Derivatives as 5-HT6 Receptor Ligands. ACS Med Chem Lett. 2010 October 14; 1(7): 340-344.
• [53] Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
• [54] Some properties of 5-hydroxytryptamine receptors in the hindquarters of the rat. Br J Pharmacol. 1979 Sep;67(1):79-85.
• [55] Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
• [56] New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020 Aug 25;12:285-300.
• [57] Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111.
• [58] Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
• [59] Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
• [60] Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501.
• [61] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [62] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [63] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [64] Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
• [65] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [66] Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30.
• [67] Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52.
• [68] Clinical pipeline report, company report or official report of Lundbeck.
• [69] A role for central A3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett. 1993 Dec 20;336(1):57-60.
• [70] 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
• [71] Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010 Sep 3;329(5996):1175-80.
• [72] 2011 Pipeline of Can-Fite BioPharm.
• [73] Synthesis and evaluation of 1,2,4-triazolo[1,5-c]pyrimidine derivatives as A2A receptor-selective antagonists. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5690-4.
• [74] Adenosine A1R/A3R (Adenosine A1 and A3 Receptor) Agonist AST-004 Reduces Brain Infarction in a Nonhuman Primate Model of Stroke. Stroke. 2022 Jan;53(1):238-248.
• [75] Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion. J Mol Cell Cardiol. 2007 Sep;43(3):262-71.
• [76] Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships. J Med Chem. 1992 Jan 24;35(2):310-9.
• [77] The 5-HT3B subunit is a major determinant of serotonin-receptor function. Nature. 1999 Jan 28;397(6717):359-63.
• [78] Novel and highly potent 5-HT3 receptor agonists based on a pyrroloquinoxaline structure. J Med Chem. 1997 Oct 24;40(22):3670-8.
• [79] Ginkgolide B and bilobalide block the pore of the 5-HT eceptor at a location that overlaps the picrotoxin binding site. Neuropharmacology. 2011 Feb-Mar;60(2-3):488-95.
• [80] Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotoni... J Med Chem. 2003 Feb 27;46(5):702-15.
• [81] Co-expression of the 5-HT(3B) subunit with the 5-HT(3A) receptor reduces alcohol sensitivity. Brain Res Mol Brain Res. 2005 Dec 14;142(2):146-50.
• [82] Pharmacological comparison of human homomeric 5-HT3A receptors versus heteromeric 5-HT3A/3B receptors. Neuropharmacology. 2001 Aug;41(2):282-4.
• [83] Metoclopramide stimulates catecholamine- and granin-derived peptide secretion from pheochromocytoma cells through activation of serotonin type 4 (5... Endocr Relat Cancer. 2009 Mar;16(1):281-90.
• [84] Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
• [85] 5-Hydroxytryptamine mediated contractions in isolated preparations of equine ileum and pelvic flexure: pharmacological characterization of a new 5-HT(4) agonist. J Vet Pharmacol Ther. 2002 Feb;25(1):49-58.
• [86] The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol. 2008 Jul;378(1):125-37.
• [87] Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome. Drugs R D. 2008;9(1):37-63.
• [88] The effects of lintopride, a 5HT-4 antagonist, on oesophageal motility. Aliment Pharmacol Ther. 1995 Oct;9(5):563-9.
• [89] The Pharmacology of TD-8954, a Potent and Selective 5-HT(4) Receptor Agonist with Gastrointestinal Prokinetic Properties. Front Pharmacol. 2011 May 30;2:25.
• [90] A randomized trial of 5-hydroxytryptamine4-receptor agonist, YKP10811, on colonic transit and bowel function in functional constipation. Clin Gastroenterol Hepatol. 2015 Apr;13(4):701-8.e1.
• [91] Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, do... Lancet Oncol. 2009 Feb;10(2):115-24.
• [92] Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2009 Jul;104(7):1831-43; quiz 1844.
• [93] Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62.
• [94] Management of postoperative nausea and vomiting: focus on palonosetron. Ther Clin Risk Manag. 2009 Feb;5(1):21-34.
• [95] Local anesthetics have different mechanisms and sites of action at recombinant 5-HT3 receptors. Reg Anesth Pain Med. 2007 Nov-Dec;32(6):462-70.
• [96] Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea.Expert Opin Investig Drugs.2005 Feb;14(2):185-93.
• [97] mu-Opioid/5-HT4 dual pharmacologically active agents-efforts towards an effective opioid analgesic with less GI and respiratory side effects (Part I). Bioorg Med Chem Lett. 2009 Oct 1;19(19):5679-83.
• [98] Effect of serotonin (5-HT)3-receptor antagonists YM060, YM114 (KAE-393), ondansetron and granisetron on 5-HT4 receptors and gastric emptying in rodents. Jpn J Pharmacol. 1995 Nov;69(3):205-14.
• [99] Interactions between corticotropin-releasing hormone and serotonin: implications for the aetiology and treatment of anxiety disorders. Handb Exp Pharmacol. 2005;(169):181-204.
• [100] Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9.
• [101] 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
• [102] Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
• [103] Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993).
• [104] Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55.
• [105] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [106] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
• [107] Selective pharmacological blockade of the 5-HT7 receptor attenuates light and 8-OH-DPAT induced phase shifts of mouse circadian wheel running activity. Front Behav Neurosci. 2015 Jan 15;8:453.
• [108] AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders. J Alzheimers Dis. 2016 May 25;53(2):583-620.
• [109] Pharmacological characteristics of ATI-9242, a Novel Atypical Antipsychotic. FASEB J, April, 2010, 24(Meeting Abstract Supplement),773.12.
• [110] 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
• [111] Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
• [112] [(3)H]-SB-269970--A selective antagonist radioligand for 5-HT(7) receptors. Br J Pharmacol. 2000 May;130(2):409-17.
• [113] Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
• [114] Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
• [115] The inhibitory effects of tramadol on 5-hydroxytryptamine type 2C receptors expressed in Xenopus oocytes. Anesth Analg. 2004 May;98(5):1401-6, table of contents.
• [116] Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulatio... Mol Pharmacol. 2008 Mar;73(3):748-57.
• [117] Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie. 2005 Sep-Oct;60(5):441-60.
• [118] Spinal serotonin receptor activation modulates the exercise ventilatory response with increased dead space in goats. Respir Physiol Neurobiol. 2008 May 31;161(3):230-8.
• [119] Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists ... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12.
• [120] SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology. 2002 Sep;27(3):430-41.
• [121] Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
• [122] Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol. 2005 Dec;167(6):1477-84.
• [123] Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells. Metallomics. 2018 Mar 1;10(3):414-425.
• [124] Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997 Jul;16(7):871-81.
• [125] Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
• [126] The organic cation transporters (OCT1, OCT2, EMT) and the plasma membrane monoamine transporter (PMAT) show differential distribution and cyclic expression pattern in human endometrium and early pregnancy decidua. Mol Reprod Dev. 2007 Oct;74(10):1303-11.
• [127] Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet. 2005 Oct;20(5):379-86.
• [128] A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
• [129] The vesicular monoamine transporter 2: an underexplored pharmacological target. Neurochem Int. 2014 Jul;73:89-97.
• [130] Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter. J Med Chem. 2018 Oct 25;61(20):9121-9131.
• [131] Gastrin-producing endocrine cells: a novel source of histamine in the rat stomach. Endocrinology. 1998 Oct;139(10):4404-15.
• [132] Histamine uptake mediated by plasma membrane monoamine transporter and organic cation transporters in rat mast cell lines. Eur J Pharmacol. 2019 Apr 15;849:75-83.
• [133] Metformin: from mechanisms of action to therapies. Cell Metab. 2014 Dec 2;20(6):953-66.
• [134] Serotonin transporter gene and treatment of alcoholism.
• [135] Role of monoamine-oxidase-A-gene variation in the development of glioblastoma in males: a case control study. J Neurooncol. 2019 Nov;145(2):287-294.
• [136] Med-psych drug-drug interactions update. Psychosomatics. 2002 May;43(3):245-7.
• [137] Migraine pharmacotherapy with oral triptans: a rational approach to clinical management. Expert Opin Pharmacother. 2000 Mar;1(3):391-404.
• [138] Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoamine oxidase. J Med Chem. 2007 Oct 4;50(20):4909-16.
• [139] Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. Clin Pharmacokinet. 2005;44(3):237-46.
• [140] Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
• [141] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [142] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [143] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [144] Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors. Leuk Res. 2007 Nov;31(11):1511-20.
• [145] Characterizing fucoxanthin as a selective dopamine D(3)/D(4) receptor agonist: Relevance to Parkinson's disease. Chem Biol Interact. 2019 Sep 1;310:108757. doi: 10.1016/j.cbi.2019.108757. Epub 2019 Jul 16.
• [146] Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
• [147] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [148] Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors. J Med Chem. 2011 Oct 27;54(20):7127-37.
• [149] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [150] Serotonin transporter mRNA expression in peripheral leukocytes of patients with major depression before and after treatment with paroxetine. Neurosci Lett. 2005 Nov 25;389(1):12-6. doi: 10.1016/j.neulet.2005.06.048.
• [151] Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline. Int J Neuropsychopharmacol. 2003 Dec;6(4):339-46. doi: 10.1017/S1461145703003663.
• [152] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [153] Serotonin transporter mRNA expression is decreased by lamivudine and ribavirin and increased by interferon in immune cells. Scand J Immunol. 2006 Feb;63(2):106-15. doi: 10.1111/j.1365-3083.2005.01715.x.
• [154] Establishment of a 13 genes-based molecular prediction score model to discriminate the neurotoxic potential of food relevant-chemicals. Toxicol Lett. 2022 Feb 1;355:1-18. doi: 10.1016/j.toxlet.2021.10.013. Epub 2021 Nov 5.
• [155] Cholesterol-lowering therapy evokes time-limited changes in serotonergic transmission. Psychiatry Res. 2005 Feb 28;133(2-3):197-203. doi: 10.1016/j.psychres.2004.11.005.
• [156] Design and synthesis of novel arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter. J Med Chem. 2011 Sep 22;54(18):6305-18. doi: 10.1021/jm200682b. Epub 2011 Aug 23.
• [157] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [158] Selective transport of monoamine neurotransmitters by human plasma membrane monoamine transporter and organic cation transporter 3. J Pharmacol Exp Ther. 2010 Dec;335(3):743-53. doi: 10.1124/jpet.110.170142. Epub 2010 Sep 21.
• [159] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [160] Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes. Front Pharmacol. 2016 Apr 26;7:111.
• [161] Evidence for a role of claudin 2 as a proximal tubular stress responsive paracellular water channel. Toxicol Appl Pharmacol. 2014 Sep 1;279(2):163-72.
• [162] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [163] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [164] Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
• [165] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [166] Exposure to Insecticides Modifies Gene Expression and DNA Methylation in Hematopoietic Tissues In Vitro. Int J Mol Sci. 2023 Mar 26;24(7):6259. doi: 10.3390/ijms24076259.
• [167] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [168] Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013 Mar;3(3):308-23.
• [169] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [170] The effect of rare human sequence variants on the function of vesicular monoamine transporter 2. Pharmacogenetics. 2004 Sep;14(9):587-94. doi: 10.1097/00008571-200409000-00003.
• [171] Assessing Vesicular Monoamine Transport and Toxicity Using Fluorescent False Neurotransmitters. Chem Res Toxicol. 2021 May 17;34(5):1256-1264. doi: 10.1021/acs.chemrestox.0c00380. Epub 2020 Dec 30.
• [172] Synaptic vesicular monoamine transporter expression: distribution and pharmacologic profile. Brain Res Mol Brain Res. 1994 Mar;22(1-4):219-26. doi: 10.1016/0169-328x(94)90050-7.
• [173] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [174] Gene expression profile of human lymphoid CEM cells sensitive and resistant to glucocorticoid-evoked apoptosis. Genomics. 2003 Jun;81(6):543-55.
• [175] Loss of striatal vesicular monoamine transporter protein (VMAT2) in human cocaine users. Am J Psychiatry. 2003 Jan;160(1):47-55. doi: 10.1176/appi.ajp.160.1.47.
• [176] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [177] Chronic ethanol exposure increases goosecoid (GSC) expression in human embryonic carcinoma cell differentiation. J Appl Toxicol. 2014 Jan;34(1):66-75.
• [178] The NRF2-mediated oxidative stress response pathway is associated with tumor cell resistance to arsenic trioxide across the NCI-60 panel. BMC Med Genomics. 2010 Aug 13;3:37. doi: 10.1186/1755-8794-3-37.
• [179] Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget. 2014 May 15;5(9):2355-71.
• [180] Exome-wide mutation profile in benzo[a]pyrene-derived post-stasis and immortal human mammary epithelial cells. Mutat Res Genet Toxicol Environ Mutagen. 2014 Dec;775-776:48-54. doi: 10.1016/j.mrgentox.2014.10.011. Epub 2014 Nov 4.
• [181] Transcriptomic?pathway?and?benchmark dose analysis of Bisphenol A, Bisphenol S, Bisphenol F, and 3,3',5,5'-Tetrabromobisphenol A in H9 human embryonic stem cells. Toxicol In Vitro. 2021 Apr;72:105097. doi: 10.1016/j.tiv.2021.105097. Epub 2021 Jan 18.
• [182] Evaluation of first generation synthetic cannabinoids on binding at non-cannabinoid receptors and in a battery of in?vivo assays in mice. Neuropharmacology. 2016 Nov;110(Pt A):143-153. doi: 10.1016/j.neuropharm.2016.07.016. Epub 2016 Jul 20.
• [183] Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.
• [184] Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer. 2010 Jun 27;9:168.
• [185] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [186] 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
• [187] Effects of progesterone treatment on expression of genes involved in uterine quiescence. Reprod Sci. 2011 Aug;18(8):781-97.
• [188] Serotonin 5-HT(2B) receptor loss of function mutation in a patient with fenfluramine-associated primary pulmonary hypertension. Cardiovasc Res. 2003 Dec 1;60(3):518-28. doi: 10.1016/j.cardiores.2003.09.015.
• [189] Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells. Cancer Med. 2017 Nov;6(11):2646-2659. doi: 10.1002/cam4.1179. Epub 2017 Sep 27.
• [190] Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):11927-32. doi: 10.1073/pnas.0609752104. Epub 2007 Jul 2.
• [191] Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12.
• [192] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [193] No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation. Pharmacogenomics J. 2007 Aug;7(4):275-81. doi: 10.1038/sj.tpj.6500418. Epub 2006 Sep 19.
• [194] Nephrotoxicity induced by cisplatin is primarily due to the activation of the 5-hydroxytryptamine degradation system in proximal renal tubules. Chem Biol Interact. 2021 Nov 1;349:109662. doi: 10.1016/j.cbi.2021.109662. Epub 2021 Sep 21.
• [195] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [196] Endometrial receptivity is affected in women with high circulating progesterone levels at the end of the follicular phase: a functional genomics analysis. Hum Reprod. 2011 Jul;26(7):1813-25.
• [197] Indomethacin and juglone inhibit inflammatory molecules to induce apoptosis in colon cancer cells. J Biochem Mol Toxicol. 2020 Feb;34(2):e22433. doi: 10.1002/jbt.22433. Epub 2020 Jan 9.
• [198] A cell impedance-based real-time in vitro assay to assess the toxicity of amphotericin B formulations. Toxicol Appl Pharmacol. 2017 Nov 1;334:18-23. doi: 10.1016/j.taap.2017.08.017. Epub 2017 Sep 1.
• [199] CBD Promotes Oral Ulcer Healing via Inhibiting CMPK2-Mediated Inflammasome. J Dent Res. 2022 Feb;101(2):206-215. doi: 10.1177/00220345211024528. Epub 2021 Jul 16.
• [200] Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway. Toxicol Sci. 2014 Feb;137(2):404-15. doi: 10.1093/toxsci/kft254. Epub 2013 Nov 5.
• [201] Anti-inflammatory effects of the GABA(B) receptor agonist baclofen in allergic contact dermatitis. Exp Dermatol. 2010 Jul 1;19(7):661-6. doi: 10.1111/j.1600-0625.2010.01076.x. Epub 2010 Feb 25.
• [202] Frankincense myrrh attenuates hepatocellular carcinoma by regulating tumor blood vessel development through multiple epidermal growth factor receptor-mediated signaling pathways. World J Gastrointest Oncol. 2022 Feb 15;14(2):450-477. doi: 10.4251/wjgo.v14.i2.450.
• [203] Sulfasalazine unveils a contact-independent HSV-TK/ganciclovir gene therapy bystander effect in malignant gliomas. Int J Oncol. 2007 Jan;30(1):283-90.
• [204] Oxidative Stress Alters miRNA and Gene Expression Profiles in Villous First Trimester Trophoblasts. Biomed Res Int. 2015;2015:257090. doi: 10.1155/2015/257090. Epub 2015 Aug 3.
• [205] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [206] ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
• [207] Reactive metabolite of gefitinib activates inflammasomes: implications for gefitinib-induced idiosyncratic reaction. J Toxicol Sci. 2020;45(11):673-680. doi: 10.2131/jts.45.673.
• [208] An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
• [209] Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
• [210] (9)-Tetrahydrocannabinol Suppresses Monocyte-Mediated Astrocyte Production of Monocyte Chemoattractant Protein 1 and Interleukin-6 in a Toll-Like Receptor 7-Stimulated Human Coculture. J Pharmacol Exp Ther. 2019 Oct;371(1):191-201. doi: 10.1124/jpet.119.260661. Epub 2019 Aug 5.
• [211] Changes in gene expression profiles in response to selenium supplementation among individuals with arsenic-induced pre-malignant skin lesions. Toxicol Lett. 2007 Mar 8;169(2):162-76. doi: 10.1016/j.toxlet.2007.01.006. Epub 2007 Jan 19.
• [212] Profiling the immunotoxicity of chemicals based on in vitro evaluation by a combination of the Multi-ImmunoTox assay and the IL-8 Luc assay. Arch Toxicol. 2018 Jun;92(6):2043-2054. doi: 10.1007/s00204-018-2199-7. Epub 2018 Mar 29.
• [213] Spironolactone induces apoptosis in human mononuclear cells. Association between apoptosis and cytokine suppression. Apoptosis. 2006 Apr;11(4):573-9. doi: 10.1007/s10495-006-4919-3.
• [214] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [215] Mechanisms of dexamethasone-induced disturbed sleep and fatigue in paediatric patients receiving treatment for ALL. Eur J Cancer. 2010 Jul;46(10):1848-55. doi: 10.1016/j.ejca.2010.03.026. Epub 2010 Apr 17.
• [216] Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
• [217] Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir Ther. 2007;12(4):489-500.
• [218] Blood cell oxidative stress precedes hemolysis in whole blood-liver slice co-cultures of rat, dog, and human tissues. Toxicol Appl Pharmacol. 2010 May 1;244(3):354-65. doi: 10.1016/j.taap.2010.01.017. Epub 2010 Feb 6.
• [219] Monomeric and oligomeric flavanols maintain the endogenous glucocorticoid response in human macrophages in pro-oxidant conditions in vitro. Chem Biol Interact. 2018 Aug 1;291:237-244.
• [220] Nicotine up-regulates IL-8 expression in human gingival epithelial cells following stimulation with IL-1 or P. gingivalis lipopolysaccharide via nicotinic acetylcholine receptor signalling. Arch Oral Biol. 2012 May;57(5):483-90. doi: 10.1016/j.archoralbio.2011.10.007. Epub 2011 Nov 25.
• [221] Ca(2+) Signaling and IL-8 Secretion in Human Testicular Peritubular Cells Involve the Cation Channel TRPV2. Int J Mol Sci. 2018 Sep 19;19(9):2829. doi: 10.3390/ijms19092829.
• [222] Nitrogen mustard prevents transport of Fra-1 into the nucleus to promote c-Fos- and FosB-dependent IL-8 induction in injured mouse epidermis. Toxicol Lett. 2020 Feb 1;319:256-263. doi: 10.1016/j.toxlet.2019.10.006. Epub 2019 Oct 19.
• [223] Nitric oxide synthase inhibitors attenuate ozone-induced airway inflammation in guinea pigs. Possible role of interleukin-8. Am J Respir Crit Care Med. 2000 Jan;161(1):249-56. doi: 10.1164/ajrccm.161.1.9804096.
• [224] Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 2010 Nov 18;363(21):1991-2003. doi: 10.1056/NEJMoa0909825.
• [225] Adenosine receptors and phosphodiesterase inhibitors stimulate Cl- secretion in Calu-3 cells. Am J Respir Cell Mol Biol. 2003 Sep;29(3 Pt 1):410-8. doi: 10.1165/rcmb.2002-0247OC. Epub 2003 Apr 24.
• [226] Modulation of deltaF508 cystic fibrosis transmembrane regulator trafficking and function with 4-phenylbutyrate and flavonoids. Am J Respir Cell Mol Biol. 2004 Sep;31(3):351-7. doi: 10.1165/rcmb.2002-0086OC. Epub 2004 Jun 10.
• [227] Proteasome-dependent pharmacological rescue of cystic fibrosis transmembrane conductance regulator revealed by mutation of glycine 622. J Pharmacol Exp Ther. 2008 Apr;325(1):89-99. doi: 10.1124/jpet.107.134502. Epub 2008 Jan 29.
• [228] Comparative pharmacology of the activity of wild-type and G551D mutated CFTR chloride channel: effect of the benzimidazolone derivative NS004. J Membr Biol. 2003 Jul 15;194(2):109-17. doi: 10.1007/s00232-003-2030-z.
• [229] Reversible silencing of CFTR chloride channels by glutathionylation. J Gen Physiol. 2005 Feb;125(2):127-41. doi: 10.1085/jgp.200409115. Epub 2005 Jan 18.
• [230] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [231] Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol. 2012 Jun 1;261(2):204-16.
• [232] Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
• [233] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [234] Linalool is a PPARalpha ligand that reduces plasma TG levels and rewires the hepatic transcriptome and plasma metabolome. J Lipid Res. 2014 Jun;55(6):1098-110.
• [235] Comparison of the effects of pioglitazone and rosiglitazone on macrophage foam cell formation. Biochem Biophys Res Commun. 2004 Oct 22;323(3):782-8.
• [236] Treatment with anticancer agents induces dysregulation of specific Wnt signaling pathways in human ovarian luteinized granulosa cells in vitro. Toxicol Sci. 2013 Nov;136(1):183-92. doi: 10.1093/toxsci/kft175. Epub 2013 Aug 16.
• [237] Progesterone increases csk homologous kinase in HMC-1560 human mast cells and reduces cell proliferation. J Cell Biochem. 2007 Dec 1;102(5):1271-80. doi: 10.1002/jcb.21357.
• [238] Cannabidiol upregulates melanogenesis through CB1 dependent pathway by activating p38 MAPK and p42/44 MAPK. Chem Biol Interact. 2017 Aug 1;273:107-114. doi: 10.1016/j.cbi.2017.06.005. Epub 2017 Jun 7.
• [239] Growth stimulation of human pulmonary adenocarcinoma cells and small airway epithelial cells by beta-carotene via activation of cAMP, PKA, CREB and ERK1/2. Int J Cancer. 2006 Mar 15;118(6):1370-80. doi: 10.1002/ijc.21537.
• [240] Estrogen and pure antiestrogen fulvestrant (ICI 182 780) augment cell-matrigel adhesion of MCF-7 breast cancer cells through a novel G protein coupled estrogen receptor (GPR30)-to-calpain signaling axis. Toxicol Appl Pharmacol. 2014 Mar 1;275(2):176-81. doi: 10.1016/j.taap.2014.01.005. Epub 2014 Jan 17.
• [241] Inhibition of activator protein 1 by barbiturates is mediated by differential effects on mitogen-activated protein kinases and the small G proteins ras and rac-1. J Pharmacol Exp Ther. 2004 Dec;311(3):1232-40. doi: 10.1124/jpet.104.071332. Epub 2004 Jul 19.
• [242] Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. Breast Cancer Res Treat. 2010 Feb;119(3):575-91. doi: 10.1007/s10549-009-0355-8. Epub 2009 Mar 15.
• [243] Effect of histamine H1 receptor antagonists on TARC/CCL17 and MDC/CCL22 production from CD14+ cells induced by antigenic stimulation in vitro. Int Arch Allergy Immunol. 2011;155(1):38-51. doi: 10.1159/000318720. Epub 2010 Nov 25.
• [244] SIRT3 Mediates the Antioxidant Effect of Hydrogen Sulfide in Endothelial Cells. Antioxid Redox Signal. 2016 Feb 20;24(6):329-43. doi: 10.1089/ars.2015.6331. Epub 2015 Nov 10.
• [245] Downregulation of mitogen-activated protein kinases (MAPKs) in chronic ethanol-induced fatty liver. Toxicol Mech Methods. 2020 Jul;30(6):407-416. doi: 10.1080/15376516.2020.1747126. Epub 2020 Apr 1.
• [246] A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16657-62. doi: 10.1073/pnas.0707936104. Epub 2007 Oct 9.
• [247] The stent-eluting drugs sirolimus and paclitaxel suppress healing of the endothelium by induction of autophagy. Am J Pathol. 2009 Nov;175(5):2226-34.
• [248] Modulation of apoptosis in HaCaT keratinocytes via differential regulation of ERK signaling pathway by flavonoids. J Biol Chem. 2005 Sep 9;280(36):31498-507. doi: 10.1074/jbc.M505537200. Epub 2005 Jul 13.
• [249] Regulatory role of nitric oxide on monocyte-derived dendritic cell functions. J Interferon Cytokine Res. 2003 Aug;23(8):423-31. doi: 10.1089/107999003322277838.
• [250] [Effects of vitamin A on the differentiation, maturation and functions of dendritic cells from cord blood]. Zhonghua Er Ke Za Zhi. 2004 May;42(5):340-3.
• [251] Characterization of drug-specific signaling between primary human hepatocytes and immune cells. Toxicol Sci. 2017 Jul 1;158(1):76-89.
• [252] Alcohol and Cannabinoids Differentially Affect HIV Infection and Function of Human Monocyte-Derived Dendritic Cells (MDDC). Front Microbiol. 2015 Dec 22;6:1452. doi: 10.3389/fmicb.2015.01452. eCollection 2015.
• [253] Histamine inhibits the production of interleukin-12 through interaction with H2 receptors. J Clin Invest. 1998 Nov 15;102(10):1866-73. doi: 10.1172/JCI3692.
• [254] Systemic drugs inducing non-immediate cutaneous adverse reactions and contact sensitizers evoke similar responses in THP-1 cells. J Appl Toxicol. 2015 Apr;35(4):398-406. doi: 10.1002/jat.3033. Epub 2014 Aug 4.
• [255] Induction of the endoplasmic reticulum stress protein GADD153/CHOP by capsaicin in prostate PC-3 cells: a microarray study. Biochem Biophys Res Commun. 2008 Aug 8;372(4):785-91.
• [256] The effect of DNA methylation inhibitor 5-Aza-2'-deoxycytidine on human endometrial stromal cells. Hum Reprod. 2010 Nov;25(11):2859-69.
• [257] Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood. 2001 Jun 1;97(11):3466-9. doi: 10.1182/blood.v97.11.3466.
• [258] Effect of serum and antioxidants on the immunogenicity of protein kinase C-activated chronic lymphocytic leukemia cells. J Immunother. 2005 Jan-Feb;28(1):28-39. doi: 10.1097/00002371-200501000-00004.
• [259] COX-2 and PPAR-gama confer cannabidiol-induced apoptosis of human lung cancer cells. Mol Cancer Ther. 2013 Jan;12(1):69-82.
• [260] Protective effects of myricitrin against osteoporosis via reducing reactive oxygen species and bone-resorbing cytokines. Toxicol Appl Pharmacol. 2014 Nov 1;280(3):550-60.
• [261] The effect of quercetin and kaempferol aglycones and glucuronides on peroxisome proliferator-activated receptor-gamma (PPAR-). Food Funct. 2015 Apr;6(4):1098-107. doi: 10.1039/c5fo00076a.
• [262] Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3951-6. doi: 10.1073/pnas.96.7.3951.
• [263] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [264] Glucosamine sulfate reduces prostaglandin E(2) production in osteoarthritic chondrocytes through inhibition of microsomal PGE synthase-1. J Rheumatol. 2012 Mar;39(3):635-44. doi: 10.3899/jrheum.110621. Epub 2011 Nov 15.
• [265] Isoniazid suppresses antioxidant response element activities and impairs adipogenesis in mouse and human preadipocytes. Toxicol Appl Pharmacol. 2013 Dec 15;273(3):435-41. doi: 10.1016/j.taap.2013.10.005. Epub 2013 Oct 12.
• [266] Regulatory role of KEAP1 and NRF2 in PPAR expression and chemoresistance in human non-small-cell lung carcinoma cells. Free Radic Biol Med. 2012 Aug 15;53(4):758-68. doi: 10.1016/j.freeradbiomed.2012.05.041. Epub 2012 Jun 7.
• [267] Aspirin inhibits MMP-9 mRNA expression and release via the PPARalpha/gamma and COX-2/mPGES-1-mediated pathways in macrophages derived from THP-1 cells. Biomed Pharmacother. 2010 Feb;64(2):118-23. doi: 10.1016/j.biopha.2009.04.033. Epub 2009 Oct 17.
• [268] Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients. Antivir Ther. 2003 Aug;8(4):323-31.
• [269] eIF4E is a critical regulator of human papillomavirus (HPV)-immortalized cervical epithelial (H8) cell growth induced by nicotine. Toxicology. 2019 May 1;419:1-10. doi: 10.1016/j.tox.2019.02.017. Epub 2019 Mar 2.
• [270] Transcriptomic Analysis of Stem Cells Treated with Moringin or Cannabidiol: Analogies and Differences in Inflammation Pathways. Int J Mol Sci. 2019 Nov 30;20(23):6039. doi: 10.3390/ijms20236039.
• [271] Antidepressant drug sertraline modulates AMPK-MTOR signaling-mediated autophagy via targeting mitochondrial VDAC1 protein. Autophagy. 2021 Oct;17(10):2783-2799. doi: 10.1080/15548627.2020.1841953. Epub 2020 Nov 9.
• [272] EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells. PLoS One. 2011;6(6):e18691. doi: 10.1371/journal.pone.0018691. Epub 2011 Jun 2.
• [273] Repression of Kisspeptin1 weakens hydrogen peroxide-caused injury in HTR8 cells via adjusting PI3K/AKT/mTOR pathway. J Biochem Mol Toxicol. 2020 May;34(5):e22461. doi: 10.1002/jbt.22461. Epub 2020 Feb 11.
• [274] Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation. J Biochem Mol Toxicol. 2018 Jan;32(1). doi: 10.1002/jbt.22007. Epub 2017 Nov 7.
• [275] Quercetin inhibits angiogenesis mediated human prostate tumor growth by targeting VEGFR- 2 regulated AKT/mTOR/P70S6K signaling pathways. PLoS One. 2012;7(10):e47516. doi: 10.1371/journal.pone.0047516. Epub 2012 Oct 18.
• [276] A comprehensive analysis of Wnt/beta-catenin signaling pathway-related genes and crosstalk pathways in the treatment of As2O3 in renal cancer. Ren Fail. 2018 Nov;40(1):331-339.
• [277] Hydroquinone-induced endoplasmic reticulum stress affects TK6 cell autophagy and apoptosis via ATF6-mTOR. Environ Toxicol. 2023 Aug;38(8):1874-1890. doi: 10.1002/tox.23814. Epub 2023 May 6.
• [278] Cannabidiol Modulates the Expression of Alzheimer's Disease-Related Genes in Mesenchymal Stem Cells. Int J Mol Sci. 2016 Dec 23;18(1):26. doi: 10.3390/ijms18010026.
• [279] Effects and mechanisms of betulinic acid on improving EGFR TKI-resistance of lung cancer cells. Environ Toxicol. 2018 Nov;33(11):1153-1159.
• [280] The protective effects of liraglutide on AD-like neurodegeneration induced by oxidative stress in human neuroblastoma SH-SY5Y cells. Chem Biol Interact. 2019 Sep 1;310:108688. doi: 10.1016/j.cbi.2019.06.001. Epub 2019 Jun 4.
• [281] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [282] Dysregulation of integrin-linked kinase (ILK) signaling in colonic polyposis. Oncogene. 2001 Sep 27;20(43):6250-7. doi: 10.1038/sj.onc.1204791.
• [283] Differential effects of simvastatin and pravastatin on expression of Alzheimer's disease-related genes in human astrocytes and neuronal cells. J Lipid Res. 2009 Oct;50(10):2095-102. doi: 10.1194/jlr.M900236-JLR200. Epub 2009 May 21.
• [284] Quercetin potentiates apoptosis by inhibiting nuclear factor-kappaB signaling in H460 lung cancer cells. Biol Pharm Bull. 2013;36(6):944-51. doi: 10.1248/bpb.b12-01004.
• [285] Suppression of NF-kappaB and GSK-3beta is involved in colon cancer cell growth inhibition by the PPAR agonist troglitazone. Chem Biol Interact. 2010 Oct 6;188(1):75-85. doi: 10.1016/j.cbi.2010.06.001. Epub 2010 Jun 9.
• [286] NGBR is required to ameliorate type 2 diabetes in mice by enhancing insulin sensitivity. J Biol Chem. 2021 Jan-Jun;296:100624. doi: 10.1016/j.jbc.2021.100624. Epub 2021 Apr 2.
• [287] -Carotene Induces Apoptosis in Human Esophageal Squamous Cell Carcinoma Cell Lines via the Cav-1/AKT/NF-B Signaling Pathway. J Biochem Mol Toxicol. 2016 Mar;30(3):148-57. doi: 10.1002/jbt.21773. Epub 2016 Jan 6.
• [288] Differential gene expression of sulindac-treated human breast epithelial cells. Int J Oncol. 2005 Dec;27(6):1727-36.
• [289] Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2716-23.
• [290] Prevention of deoxycholate-induced gastric apoptosis by aspirin: roles of NF-kappaB and PKC signaling. J Surg Res. 2008 Mar;145(1):66-73. doi: 10.1016/j.jss.2007.04.039. Epub 2007 Jul 20.
• [291] Peroxisome proliferator-activated receptor-gamma agonists inhibit respiratory syncytial virus-induced expression of intercellular adhesion molecule-1 in human lung epithelial cells. Immunology. 2007 May;121(1):71-81. doi: 10.1111/j.1365-2567.2006.02539.x.
• [292] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [293] Glucosamine regulation of LPS-mediated inflammation in human bronchial epithelial cells. Eur J Pharmacol. 2010 Jun 10;635(1-3):219-26. doi: 10.1016/j.ejphar.2010.02.044. Epub 2010 Mar 20.
• [294] Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate. J Rheumatol. 2007 Sep;34(9):1817-22. Epub 2007 Aug 1.
• [295] In vitro study of transporters involved in intestinal absorption of inorganic arsenic. Chem Res Toxicol. 2012 Feb 20;25(2):446-53. doi: 10.1021/tx200491f. Epub 2012 Jan 26.
• [296] Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
• [297] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [298] From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
• [299] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [300] Characterization of human liver thermostable phenol sulfotransferase (SULT1A1) allozymes with 3,3',5-triiodothyronine as the substrate. J Endocrinol. 2001 Dec;171(3):525-32.
• [301] Enzymatic characterization and interspecies difference of phenol sulfotransferases, ST1A forms. Drug Metab Dispos. 2001 Mar;29(3):274-81.
• [302] Sulfation of benzyl alcohol by the human cytosolic sulfotransferases (SULTs): a systematic analysis. J Appl Toxicol. 2016 Sep;36(9):1090-4.
• [303] Inhibition of human phenol and estrogen sulfotransferase by certain non-steroidal anti-inflammatory agents. Curr Drug Metab. 2006 Oct;7(7):745-53.
• [304] Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
• [305] Methotrexate induction of human sulfotransferases in Hep G2 and Caco-2 cells. J Appl Toxicol. 2005 Sep-Oct;25(5):354-60.
• [306] Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells. Chem Biol Interact. 2013 Apr 25;203(2):412-22. doi: 10.1016/j.cbi.2013.03.011. Epub 2013 Mar 22.
• [307] Cigarette smoke and asbestos activate poly-ADP-ribose polymerase in alveolar epithelial cells. J Investig Med. 2001 Jan;49(1):68-76. doi: 10.2310/6650.2001.34092.
• [308] Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 2004 May 1;64(9):3022-9. doi: 10.1158/0008-5472.can-03-1880.
• [309] The antidepressants imipramine, clomipramine, and citalopram induce apoptosis in human acute myeloid leukemia HL-60 cells via caspase-3 activation. J Biochem Mol Toxicol. 1999;13(6):338-47. doi: 10.1002/(sici)1099-0461(1999)13:6<338::aid-jbt8>3.0.co;2-7.
• [310] Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000 Mar;6(3):891-900.
• [311] Investigation of molecular mechanisms underlying the antiproliferative effects of colchicine against PC3 prostate cancer cells. Toxicol In Vitro. 2021 Jun;73:105138. doi: 10.1016/j.tiv.2021.105138. Epub 2021 Mar 6.
• [312] Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther. 2005 Feb;4(2):291-304.
• [313] Methotrexate induces poly(ADP-ribose) polymerase-dependent, caspase 3-independent apoptosis in subsets of proliferating CD4+ T cells. Clin Exp Immunol. 2007 May;148(2):288-95. doi: 10.1111/j.1365-2249.2007.03335.x. Epub 2007 Feb 7.
• [314] Functional characterization of N-octyl 4-methylamphetamine variants and related bivalent compounds at the dopamine and serotonin transporters using Ca(2+) channels as sensors. Toxicol Appl Pharmacol. 2021 May 15;419:115513. doi: 10.1016/j.taap.2021.115513. Epub 2021 Mar 27.
• [315] Dopamine transporter gene associated with diminished subjective response to amphetamine. Neuropsychopharmacology. 2005 Mar;30(3):602-9. doi: 10.1038/sj.npp.1300637.
• [316] Pharmacological Chaperones of the Dopamine Transporter Rescue Dopamine Transporter Deficiency Syndrome Mutations in Heterologous Cells. J Biol Chem. 2016 Oct 14;291(42):22053-22062. doi: 10.1074/jbc.M116.749119. Epub 2016 Aug 23.
• [317] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [318] Pharmacological characterization of the aminorex analogs 4-MAR, 4,4'-DMAR, and 3,4-DMAR. Neurotoxicology. 2019 May;72:95-100. doi: 10.1016/j.neuro.2019.02.011. Epub 2019 Feb 15.
• [319] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [320] Pyrethroid pesticide-induced alterations in dopamine transporter function. Toxicol Appl Pharmacol. 2006 Mar 15;211(3):188-97. doi: 10.1016/j.taap.2005.06.003. Epub 2005 Jul 11.
• [321] Benzo[a]pyrene-induced changes in microRNA-mRNA networks. Chem Res Toxicol. 2012 Apr 16;25(4):838-49.
• [322] Effect of all-trans retinoic acid on sodium/iodide symporter expression, radioiodine uptake and gene expression profiles in a human anaplastic thyroid carcinoma cell line. Nucl Med Biol. 2006 Oct;33(7):875-82. doi: 10.1016/j.nucmedbio.2006.07.004.
• [323] Solvent effect on cDNA-expressed human sulfotransferase (SULT) activities in vitro. Drug Metab Dispos. 2003 Nov;31(11):1300-5.
• [324] Identification by automated screening of a small molecule that selectively eliminates neural stem cells derived from hESCs but not dopamine neurons. PLoS One. 2009 Sep 23;4(9):e7155.
• [325] In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. Mol Cancer Ther. 2005 Jun;4(6):885-900.
• [326] Megadose vitamin C suppresses sulfoconjugation in human colon carcinoma cell line Caco-2. Toxicol In Vitro. 2011 Mar;25(2):500-4.
• [327] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [328] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [329] Simvastatin protects neurons from cytotoxicity by up-regulating Bcl-2 mRNA and protein. J Neurochem. 2007 Apr;101(1):77-86. doi: 10.1111/j.1471-4159.2006.04375.x. Epub 2007 Jan 4.
• [330] Chelation and intercalation: complementary properties in a compound for the treatment of Alzheimer's disease. J Struct Biol. 2000 Jun;130(2-3):209-16. doi: 10.1006/jsbi.2000.4285.
• [331] Increased processing of APLP2 and APP with concomitant formation of APP intracellular domains in BDNF and retinoic acid-differentiated human neuroblastoma cells. J Neurochem. 2005 Nov;95(4):1059-68. doi: 10.1111/j.1471-4159.2005.03440.x. Epub 2005 Sep 7.
• [332] Comparison of base-line and chemical-induced transcriptomic responses in HepaRG and RPTEC/TERT1 cells using TempO-Seq. Arch Toxicol. 2018 Aug;92(8):2517-2531.
• [333] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [334] Synergistic effects of iron and aluminum on stress-related gene expression in primary human neural cells. J Alzheimers Dis. 2005 Nov;8(2):117-27; discussion 209-15. doi: 10.3233/jad-2005-8204.
• [335] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [336] Development of an alternative zebrafish model for drug-induced intestinal toxicity. J Appl Toxicol. 2018 Feb;38(2):259-273. doi: 10.1002/jat.3520. Epub 2017 Oct 13.
• [337] The effects of quercetin in cultured human RPE cells under oxidative stress and in Ccl2/Cx3cr1 double deficient mice. Exp Eye Res. 2010 Jul;91(1):15-25.
• [338] Gaseous nitrogen oxide promotes human lung cancer cell line A549 migration, invasion, and metastasis via iNOS-mediated MMP-2 production. Toxicol Sci. 2008 Dec;106(2):364-75. doi: 10.1093/toxsci/kfn195. Epub 2008 Sep 16.
• [339] Mechanism of simvastatin-induced K562 cell apoptosis. Pharmacology. 2009;84(4):191-5. doi: 10.1159/000235907. Epub 2009 Sep 2.
• [340] The anti-inflammatory flavones quercetin and kaempferol cause inhibition of inducible nitric oxide synthase, cyclooxygenase-2 and reactive C-protein, and down-regulation of the nuclear factor kappaB pathway in Chang Liver cells. Eur J Pharmacol. 2007 Feb 28;557(2-3):221-9.
• [341] Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
• [342] D-Penicillamine targets metastatic melanoma cells with induction of the unfolded protein response (UPR) and Noxa (PMAIP1)-dependent mitochondrial apoptosis. Apoptosis. 2012 Oct;17(10):1079-94.
• [343] Integrated analysis of rifampicin-induced microRNA and gene expression changes in human hepatocytes. Drug Metab Pharmacokinet. 2014;29(4):333-40.
• [344] Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
• [345] Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36.
• [346] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [347] LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188.
• [348] Molecular Insights into Human Monoamine Oxidase B Inhibition by the Glitazone Anti-Diabetes Drugs. ACS Med Chem Lett. 2011 Oct 15;3(1):39-42.
• [349] Chromone, a privileged scaffold for the development of monoamine oxidase inhibitors. J Med Chem. 2011 Jul 28;54(14):5165-73.
• [350] Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
• [351] Combining initro and in silico approaches to evaluate the multifunctional profile of rosmarinic acid from Blechnum brasiliense on targets related to neurodegeneration. Chem Biol Interact. 2016 Jul 25;254:135-45.
• [352] Nonclinical Evaluation of Antibacterial Oxazolidinones Contezolid and Contezolid Acefosamil with Low Serotonergic Neurotoxicity. Chem Res Toxicol. 2021 May 17;34(5):1348-1354. doi: 10.1021/acs.chemrestox.0c00524. Epub 2021 Apr 29.
• [353] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [354] Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
• [355] Nicotinic modulation of gene expression in SH-SY5Y neuroblastoma cells. Brain Res. 2006 Oct 20;1116(1):39-49.
• [356] Environmental pollutant induced cellular injury is reflected in exosomes from placental explants. Placenta. 2020 Jan 1;89:42-49. doi: 10.1016/j.placenta.2019.10.008. Epub 2019 Oct 17.
• [357] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [358] Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms. J Am Coll Cardiol. 2003 Sep 17;42(6):1115-9. doi: 10.1016/s0735-1097(03)00921-5.
• [359] Pro-apoptotic role of integrin 3 in glioma cells. J Neurochem. 2011 May;117(3):494-503. doi: 10.1111/j.1471-4159.2011.07219.x. Epub 2011 Mar 15.
• [360] In vitro dual effect of arsenic trioxide on hemopoiesis: inhibition of erythropoiesis and stimulation of megakaryocytic maturation. Blood Cells Mol Dis. 2006 Jan-Feb;36(1):59-76. doi: 10.1016/j.bcmd.2005.10.005. Epub 2005 Dec 15.
• [361] The differential cancer growth associated with anaesthetics in a cancer xenograft model of mice: mechanisms and implications of postoperative cancer recurrence. Cell Biol Toxicol. 2023 Aug;39(4):1561-1575. doi: 10.1007/s10565-022-09747-9. Epub 2022 Aug 12.
• [362] Grouping of histone deacetylase inhibitors and other toxicants disturbing neural crest migration by transcriptional profiling. Neurotoxicology. 2015 Sep;50:56-70.
• [363] Proteomic analysis of human adipose tissue after rosiglitazone treatment shows coordinated changes to promote glucose uptake. Obesity (Silver Spring). 2010 Jan;18(1):27-34. doi: 10.1038/oby.2009.208. Epub 2009 Jun 25.
• [364] Dose- and time-dependent transcriptional response of Ishikawa cells exposed to genistein. Toxicol Sci. 2016 May;151(1):71-87.
• [365] Progesterone regulation of implantation-related genes: new insights into the role of oestrogen. Cell Mol Life Sci. 2007 Apr;64(7-8):1009-32.